Sorry, you need to enable JavaScript to visit this website.

TRD Dosing & Administration | SPRAVATO® (esketamine) HCP

About SPRAVATO®

MDSI=depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Treatment-Resistant Depression (TRD) Dosing and Administration Overview1

TRD Dosing Frequency and Strengths are Flexible1

  • SPRAVATO® is administered by the patient at a certified treatment center where the patient is monitored by a healthcare provider for at least two hours
Person wearing brown shirt in orange circle Actor portrayal.
Nasal spray and person reclining in chair red icon

Administration

  • Patient-administered under supervision of a healthcare provider (e.g., a psychiatrist, nurse, or nurse practitioner) to assess blood pressure and monitor for other potential adverse effects
Eye red icon

Monitoring & Discharge

  • Observation by a healthcare provider will be required for at least 2 hours after treatment
  • Patients should not drive or operate heavy machinery until the next day and should coordinate transportation after treatment
Careful consideration is advised prior to treatment of individuals with a history of substance use disorder, including alcohol. Monitoring for signs of abuse and dependence is recommended.

Dosing SPRAVATO®

Dosing SPRAVATO® induction and optimization/maintenance frequency
  • SPRAVATO® must be taken with an oral AD
  • SPRAVATO® is self-administered only under the supervision of a healthcare provider
  • Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment
  • Dosing frequency should be individualized to the lowest frequency required to maintain remission/response

Reference:

1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.